SGMT
Sagimet Biosciences Inc.6.05
+0.02+0.33%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
196.76MP/E (TTM)
-Basic EPS (TTM)
-1.78Dividend Yield
0%Recent Filings
10-K
FY2025 results
Sagimet Biosciences posted a FY2025 net loss of $51.0M on $56.9M operating expenses, up 12% from $45.6M loss in FY2024, with R&D steady at $39.1M amid denifanstat Phase 3 MASH startup offset by FASCINATE-2 wind-down while TVB-3567 Phase 1 acne ramped; cash burned $45.7M operationally to end with $113.1M runway. Q4 saw denifanstat-resmetirom Phase 1 PK complete successfully with no safety signals, paving Phase 2 F4 MASH in H2 2026, while Ascletis gained China NMPA NDA acceptance for denifanstat acne. No revenue, no debt; $75M ATM untapped. Cash funds operations 12+ months. IP disputes could derail pipeline momentum.
8-K
Q4 results, combo trial advances
Sagimet reported Q4/full-year 2025 results, with cash at $113.1M funding operations through Q3 2027, yet net loss widened to $51.0M from $45.6M. Completed safe Phase 1 PK trial of denifanstat/resmetirom combo; Phase 2 in F4 MASH set for 2H 2026. Cash burn eased. Ascletis' acne NDA accepted by China NMPA.
8-K
Positive denifanstat acne safety data
Sagimet announced positive 52-week safety data from partner Ascletis' open-label Phase 3 extension trial of denifanstat in moderate-to-severe acne patients. Denifanstat proved well-tolerated; only dry eye (5.5%) and dry skin (5.2%) exceeded 5% incidence, with all related AEs mild/moderate and no discontinuations. Builds FASN inhibition confidence. Data sharing planned at congresses.
8-K
Positive denifanstat-resmetirom Phase 1
Sagimet announced positive Phase 1 PK results for denifanstat-resmetirom combo on December 18, 2025. The pairing proved well-tolerated, with no SAEs or discontinuations, supporting complementary MOAs against MASH drivers. Phase 2 proof-of-concept in F4 cirrhosis patients targets 2H 2026 start. No approved F4 treatments exist yet.
8-K
Sagimet licenses resmetirom API
Sagimet Biosciences secured a global exclusive license from TAPI for innovative resmetirom API forms to advance its denifanstat fixed-dose combination for MASH cirrhosis. Following a $2.5 million upfront via term sheet, TAPI eyes low single-digit royalties and up to $5.5 million milestones. Phase 1 PK trial data due end-2025. License bolsters Phase 3 plans, yet hinges on trial success.
AGTX
Agentix Corp.
0.04+0.00
ALT
Altimmune, Inc.
5.03-0.25
ETNB
89bio, Inc.
14.84+0.00
FBRX
Forte Biosciences, Inc.
23.27+1.31
GNTA
Genenta Science S.p.A.
1.32-0.10
IMA
ImageneBio, Inc.
6.25+0.08
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
SMMT
Summit Therapeutics Inc.
17.23-0.15
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02